PT-141 Peptide (Bremelanotide / Vyleesi): The Sexual Health Peptide
PT-141 is the only FDA-approved peptide for sexual desire. Brand name Vyleesi, generic name bremelanotide. It works on your brain, not your blood flow. Viagra handles the plumbing. PT-141 handles the wanting.
How does PT-141 work?
PT-141 (bremelanotide) is a melanocortin receptor agonist. It activates MC3R and MC4R receptors in the hypothalamus, the part of your brain that regulates sexual desire and arousal. This is a fundamentally different mechanism than PDE5 inhibitors (Viagra, Cialis) which work on blood vessel dilation in the genitals.
The distinction matters: Viagra requires physical stimulation to work and only addresses erectile function. PT-141 increases spontaneous desire, arousal, and sexual satisfaction. It works upstream of the physical response. You do not need to be in the moment for it to take effect. You start wanting to be in the moment. The FDA approval trial (RECONNECT) showed statistically significant improvement in desire and reduction in distress in women with HSDD (Kingsberg et al., Obstet Gynecol 2019).
The compound
You have low sexual desire that is not explained by relationship issues, medication side effects, or other medical conditions. The desire circuitry itself has gone quiet.
You only need erectile function (Viagra/Cialis is simpler and cheaper). Or if your low desire started with a new medication — address the medication first.
Why it is the standard
PT-141 targets the melanocortin system in the hypothalamus — the part of your brain that governs desire and arousal. Nothing else on the market targets this pathway for sexual function. The RECONNECT trials enrolled over 1,200 women and showed statistically significant improvement in desire (FSFI) and reduction in distress (FSDS). For men, clinical trials showed improved erection quality including in Viagra non-responders (Diamond et al., Int J Impot Res 2005). The effect is not dramatic by the numbers, but for people who have tried everything else, it represents a mechanism that nothing else targets.
Melanotan II is the tanning peptide on the beauty page, but it shows up in sexual health conversations because it activates the same melanocortin receptors as PT-141. The libido increase is a known side effect of MT-II, not its primary purpose. Some people use MT-II specifically for the sexual effects, but the tanning, nausea, and mole-darkening come along for the ride. PT-141 was developed as a more targeted melanocortin agonist specifically to isolate the sexual desire effect from the tanning effect. If your goal is sexual health only, PT-141 is the right tool. MT-II is the blunt instrument.
PT-141 for women
This is the FDA-approved indication. Vyleesi was approved in June 2019 for HSDD (hypoactive sexual desire disorder) in premenopausal women. HSDD is defined as persistently low sexual desire that causes personal distress. It is not about frequency. It is about wanting.
The RECONNECT trials enrolled over 1,200 women. The primary endpoints were improvement in desire (measured by the Female Sexual Function Index) and reduction in distress (Female Sexual Distress Scale). Both were statistically significant vs placebo. The effect is not dramatic by the numbers, but for women who have tried everything else, it represents a mechanism that nothing else targets.
- Premenopausal women with HSDD where the low desire is not explained by relationship issues, medication side effects (SSRIs are a common culprit), or other medical conditions.
- PT-141 for women works best when the desire circuitry itself has gone quiet, not when external factors are suppressing it.
- Postmenopausal women (not studied in the FDA trial, though off-label use exists).
- Women with uncontrolled hypertension or cardiovascular disease.
- Women on medications that raise blood pressure.
- If your low desire started with a new medication, talk to your prescriber about the medication first.
PT-141 for men
Not FDA-approved for men, but clinical trials showed efficacy for erectile dysfunction, including in men who did not respond to Viagra (Diamond et al., Int J Impot Res 2005). PT-141 for men works through the same melanocortin pathway. It increases desire and arousal centrally, and the downstream effect includes improved erection quality.
The male use case is broader than ED. Some men have the physical capability but diminished desire. Testosterone is the usual first-line treatment, but if T levels are normal and desire is still low, PT-141 targets a pathway that testosterone does not. Men also use it recreationally for enhanced arousal and sexual performance.
- Different tools. Viagra is faster, cheaper, and works purely on blood flow. PT-141 addresses desire and arousal centrally.
- Can be combined. Some clinics prescribe both: PT-141 for the desire component, Viagra for the mechanical component.
- Viagra non-responders. PT-141 showed efficacy in men who did not respond to PDE5 inhibitors, because it works through an entirely different pathway.
PT-141 vs Viagra comparison
They work through completely different mechanisms and can be used together. Viagra gives you the ability. PT-141 gives you the interest.
PT-141 dosage protocol
- Standard dose: 1.75 mg subcutaneous injection into the abdomen or thigh. This is the FDA-approved dose for Vyleesi.
- Timing: Inject at least 45 minutes before anticipated sexual activity. PT-141 onset time is typically 30-60 minutes. Peak effect at 1-2 hours.
- Frequency limits: Maximum one dose per 24 hours. Maximum 8 doses per month. This is not a daily medication. It is on-demand, like Viagra. The 8/month cap is based on the clinical trial protocol.
- Lower dose option: Some people use 1 mg instead of 1.75 mg to reduce nausea while maintaining the desire effect. The nausea is dose-dependent. Starting at 1 mg and adjusting up is a common approach.
- PT-141 nasal spray: Available through compounding pharmacies. The nasal route was studied in earlier Phase 2 trials but the FDA approved injection only. Nasal bioavailability is lower and more variable than SubQ. If you prefer nasal, expect to need a higher dose for the same effect.
How long does PT-141 last? Effects typically begin 30-60 minutes after injection and last 6-12 hours. Most people report peak effect at 1-2 hours. Some report a lingering sense of increased desire into the following day. The half-life of bremelanotide is approximately 2.7 hours, but the downstream neurological effects outlast the drug's presence in the blood. This is not like Viagra where the window is clearly defined. PT-141's effect on desire is more of a gradient.
Cost and access: Vyleesi (branded, FDA-approved for women): $800-1,000 per dose through specialty pharmacies. Insurance coverage is inconsistent. Compounded PT-141 through a telehealth clinic: $50-150 per vial (multiple doses). Research-grade PT-141: $30-60 per 10 mg vial (roughly 5 doses at 1.75 mg). If sourcing compounded or research-grade, vet your supplier and check the COA.
PT-141 side effects
Side effects from the RECONNECT trial data:
If something feels wrong after injecting, the side effects troubleshooter covers common injection reactions.
The FDA-approved form of PT-141 (Vyleesi) comes from a licensed pharmacy. Compounded PT-141 through telehealth clinics or research suppliers does not have the same oversight. If you are sourcing compounded or research-grade PT-141, vet your supplier before you inject. Check the Certificate of Analysis (COA): it should include HPLC purity (98%+), mass spec identity confirmation, and come from a named independent lab you can verify.
Who should not use PT-141
Frequently asked questions
Viagra works on blood flow (PDE5 inhibition). PT-141 works on desire (melanocortin receptors in the brain). Different mechanisms, different targets. Viagra gives you the ability. PT-141 gives you the interest. They can be combined. Full PT-141 profile.
Yes, off-label. Clinical trials showed improved erection quality in men with ED, including Viagra non-responders. The dose and timing are the same as for women: 1.75 mg SubQ, 45 minutes before.
40% of people get it. It typically lasts 1-2 hours. It is the number one complaint. Starting at 1 mg instead of 1.75 mg reduces it significantly. Anti-nausea medication (ondansetron) before dosing helps. Most people consider it a worthwhile trade-off.
The FDA protocol caps it at 8 doses per month, maximum 1 per 24 hours. That is roughly twice a week. Exceeding 8/month is not studied and the skin darkening risk increases with cumulative use.
Injection is the FDA-approved route and has more predictable absorption. Nasal spray is available through compounders but bioavailability is lower. Most protocols use SubQ injection for consistent dosing.
- RECONNECT trial (FDA approval): Kingsberg et al., Obstet Gynecol 2019
- PT-141 in male ED: Diamond et al., Int J Impot Res 2005
- Melanocortin receptors and sexual function: Hadley, Peptides 2005
- Bremelanotide pharmacology: Clayton et al., J Sex Med 2016
Where to go from here
Also: every question · storage guide · something feels off?
Content reviewed against PubMed, FDA prescribing information, and clinical trial data. Evidence tiers assigned using the vialprep methodology. Last reviewed September 2026. This content is not medical advice. Talk to a licensed clinician before starting any protocol.